Rilotumumab is a monoclonal antibody that targets the hepatocyte growth factor (HGF) and is primarily investigated for its potential in cancer therapy, particularly in treating gastric and other solid tumors. It functions by inhibiting the interaction between HGF and its receptor, c-Met, which is often overexpressed in various cancers and is associated with tumor growth, metastasis, and resistance to therapy. Rilotumumab is designed to disrupt this signaling pathway, thereby potentially reducing tumor proliferation and enhancing the effectiveness of other anticancer treatments. The substance is characterized by its specificity for HGF, which allows for targeted therapeutic strategies. As a biologic agent, it is produced through recombinant DNA technology and is typically administered via injection. Clinical trials have explored its efficacy and safety profile, although its use may be limited by factors such as patient selection and the presence of biomarkers. Overall, Rilotumumab represents a promising approach in the field of targeted cancer therapies.

Rilotumumab

872514-65-3: Rilotumumab is a monoclonal antibody that targets the hepatocyte growth factor (HGF) and is primarily investigated for its potential in cancer therapy, particularly in treating gastric and other solid tumors. It functions by inhibiting the interaction between HGF and its receptor, c-Met, which is often overexpressed in various cancers and is associated with tumor growth, metastasis, and resistance to therapy. Rilotumumab is designed to disrupt this signaling pathway, thereby potentially reducing tumor proliferation and enhancing the effectiveness of other anticancer treatments. The substance is characterized by its specificity for HGF, which allows for targeted therapeutic strategies. As a biologic agent, it is produced through recombinant DNA technology and is typically administered via injection. Clinical trials have explored its efficacy and safety profile, although its use may be limited by factors such as patient selection and the presence of biomarkers. Overall, Rilotumumab represents a promising approach in the field of targeted cancer therapies.

<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>

<p>Anti-Human HGF Monoclonal Antibody</p>

CAS 872514-65-3

Rilotumumab

Rilotumumab

Ref: TM-T76758

Rilotumumab

Ref: 3D-CLA1225